BN Business News
Add your company to Business Communicator →

Company announcements · 19/11/20261 min read

Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

EDITORIAL ILLUSTRATIONCACompany announcementsBN
Illustration generated by Business News; it is not a source photograph.

Summary

30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →